The 204 references in paper A. Masliansky L., V. Mazurov I., E. Zotkin G., E. Ilivanova P., Areg Totolian A., А. Маслянский Л., В. Мазуров И., Е. Зоткин Г., Е. Иливанова П., Арег Тотолян А. (2014) “АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ // ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES” / spz:neicon:mimmun:y:2007:i:1:p:15-34

1
Baecklund E., Askling J., Rosenquist R., Ekbom A., Klareskog L. Rheumatoid arthritis and malignant lymphomas // Curr. Opin. Rheumatol. – 2004. – Vol. 1, N 3. – P. 254-261.
(check this in PDF content)
2
Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., Olsson H., Jacobsson L.T. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk
(check this in PDF content)
3
Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., Gromnica-
(check this in PDF content)
4
Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents // Arthritis Rheum. – 2005. – Vol. 52, N 11. – P. 3403-3412.
(check this in PDF content)
5
Marmont A.M. Stem cell transplantation for severe autoimmune diseases: progress and problems // Haematologica. – 1998. – Vol. 83, N 8. – P. 733-743.
(check this in PDF content)
6
Lorenz H.M., Herrmann M., Kalden J.R. The pathogenesis of autoimmune diseases // Scand. J. Clin. Lab. Invest. Suppl. – 2001. – Vol. 235. – P. 16-26.
(check this in PDF content)
7
Panayi G.S., Corrigall V.M., Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts // Rheum. Dis. Clin. North. Am. – 2001. – Vol. 27, N 2. – P. 317-334.
(check this in PDF content)
8
Weyand C.M., Bryl E., Goronzy J.J. The role of T-cells in rheumatoid arthritis // Arch. Immunol. Ther. Exp. (Warsz.). – 2000. – Vol. 48, N 5. – P. 429-35.
(check this in PDF content)
9
Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., Burmester G.R. Macrophages in rheumatoid arthritis // Arthritis Res. – 2000. – Vol. 2, N 3. – P. 189-202.
(check this in PDF content)
10
Imamura F., Aono H., Hasunuma T., Sumida T., Tateishi H., Maruo S., Nishioka K. Monoclonal expansion of synoviocytes in rheumatoid arthritis // Arthritis Rheum. – 1998. – Vol. 41, N 11. – P. 19791986.
(check this in PDF content)
11
Isaacs J.D., Burrows N., Wing M., Keogan M.T., Rebello P.R., Watts R.A., Pye R.J., Norris P., Hazelman B.L., Hale G., Waldmann H. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease //
(check this in PDF content)
12
Matteson E.L., Yocum D.E., St Clair E.W.,
(check this in PDF content)
13
Achkar A.A., Thakor M.S., Jacobs M.R., Hays A.E., Heitman C.K., Johnston J.M. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection // Arthritis Rheum. –
(check this in PDF content)
14
Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., Brenner M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis // Science. – 2002. – Vol. 297, N 5587. – P. 1689-1692.
(check this in PDF content)
15
Lovgren T., Eloranta M.L., Bave U., Alm G.V., Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG // Arthritis Rheum. –
(check this in PDF content)
16
Martin F., Chan A.C. B-cell immunobiology in disease: evolving concepts from the clinic // Annu. Rev. Immunol. – 2006. – Vol. 24. – P. 467-496.
(check this in PDF content)
17
Vallin H., Perers A., Alm G.V., Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus // J. Immunol. – 1999. – Vol. 163,
(check this in PDF content)
18
Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibodyindependent role for B cells in murine lupus // J. Exp. Med. – 1999. – Vol. 189, N 10. – P. 1639-1648.
(check this in PDF content)
19
Wong F.S., Wen L., Tang M., Ramanathan M., Visintin I., Daugherty J., Hannum L.G., Janeway Jr. C.A., Shlomchik M.J. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse // Diabetes. – 2004. – Vol. 53, N 10. – P. 2581-2587.
(check this in PDF content)
20
Doodes P.D., Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis // J. Immunol. – 2005. – Vol. 174, N 6. – P. 3781-3788.
(check this in PDF content)
21
Soderstrom N.A.B. Organization of the invading lymphoid tissue in human lymphoid thyroiditis // Scand. J. Immunol. – 1974. – Vol. 3, N 3. – P. 295-301.
(check this in PDF content)
22
Prineas J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord // Science. – 1979. – Vol. 203, N 4385. – P. 1123-1125.
(check this in PDF content)
23
Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren’s syndrome // J. Clin. Invest. – 1998. – Vol. 102, N 5. – P. 938-946.
(check this in PDF content)
24
Lorenz R.G., Chaplin D.D., McDonald K.G., McDonough J.S., Newberry R.D. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function //
(check this in PDF content)
25
Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Forster R., Sedgwick J.D., Browning J.L., Lipp M., Cyster J.G. A chemokine-driven positive feedback 12. 13.
(check this in PDF content)
26
Mariathasan S., Matsumoto M., Baranyay F., Nahm M.H., Kanagawa O., Chaplin D.D. Absence of lymph nodes in lymphotoxin-alpha (LT alpha)deficient mice is due to abnormal organ development, not defective lymphocyte migration // J. Inflamm. –
(check this in PDF content)
27
Matsumoto M., Mariathasan S., Nahm M.H., Baranyay F., Peschon J.J., Chaplin D.D. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers // Science. – 1996. – Vol. 271, N 5253. – P. 1289-1291.
(check this in PDF content)
28
Ngo V.N., Cornall R.J., Cyster J.G. Splenic T-zone development is B cell dependent // J. Exp. Med. – 2001. – Vol. 194, N 11. – P. 1649-1660.
(check this in PDF content)
29
Kurt-Jones E.A., Liano D., HayGlass K.A., Benacerraf B., Sy M.S., Abbas A.K. The role of antigen-presenting B cells in T cell priming in vivo.
(check this in PDF content)
30
Studies of B cell-deficient mice // J. Immunol. – 1988. – Vol. 140, N 11. – P. 3773-3778.
(check this in PDF content)
31
Chan O., Shlomchik M.J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice // J. Immunol. – 1998. – Vol. 160, N 1. – P. 51-59.
(check this in PDF content)
32
Takemura S., Klimiuk P.A., Braun A., Goronzy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent // J. Immunol. – 2001. – Vol. 167, N 8. – P. 4710-4718.
(check this in PDF content)
33
Olson T.S., Bamias G., Naganuma M., Rivera-
(check this in PDF content)
34
Nieves J., Burcin T.L., Ross W., Morris M.A., Pizarro T.T., Ernst P.B., Cominelli F., Ley K. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease // J. Clin Invest. – 2004. – Vol. 114, N 3. – P. 389-398.
(check this in PDF content)
35
Yu S., Maiti P.K., Dyson M., Jain R., Braley-
(check this in PDF content)
36
Mullen H. B cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis // J. Exp. Med. – 2006. – Vol. 203, N 2. – P. 349-358.
(check this in PDF content)
37
Pistoia V. Production of cytokines by human B cells in health and disease // Immunol. Today. – 1997. – Vol. 18, N 7. – P. 343-350.
(check this in PDF content)
38
Mewar D., Wilson A.G. Autoantibodies in rheumatoid arthritis: a review // Biomed. Pharmacother. – 2006. – Vol. 60, N 10. – P. 648-655.
(check this in PDF content)
39
Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., Habibuw M.R., Vandenbroucke J.P., Dijkmans B.A. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial
(check this in PDF content)
40
Binder M., Otto F., Mertelsmann R., Veelken H., Trepel M. The epitope recognized by rituximab // Blood. – 2006. – Vol. 108, N 6. – P. 1975-1978. 24. 25.
(check this in PDF content)
41
Protheroe A., Edwards J.C., Simmons A., Maclennan K., Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin’s lymphoma // Rheumatology (Oxford). – 1999. – Vol. 38, N 11. – P. 1150-1152.
(check this in PDF content)
42
Leandro M.J., Edwards J.C., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B-lymphocyte depletion // Ann. Rheum. Dis. – 2002. – Vol. 61, N 10. – P. 883-888.
(check this in PDF content)
43
Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. – 2004. – Vol. 350, N 25. –
(check this in PDF content)
44
Emery P., Fleischmann R., Filipowicz-
(check this in PDF content)
45
Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., Racewicz A.J., van Vollenhoven R.F.,
(check this in PDF content)
46
Li N.F., Agarwal S., Hessey E.W., Shaw T.M. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial // Arthritis
(check this in PDF content)
47
Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., Hessey E.W., Shaw T., Totoritis M.C. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis
(check this in PDF content)
48
Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients // Rheumatology (Oxford). – 2005. – Vol. 44, N 12. –
(check this in PDF content)
49
Anolik J.H., Barnard J., Cappione A., Pugh-
(check this in PDF content)
50
Bernard A.E., Felgar R.E., Looney R.J., Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus // Arthritis Rheum. – 2004. – Vol. 50, N 11. – P. 3580-3590.
(check this in PDF content)
51
Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab // Arthritis Rheum. – 2004. – Vol. 50, N 8. –
(check this in PDF content)
52
Pijpe J., van Imhoff G.W., Spijkervet F.K.,
(check this in PDF content)
53
Roodenburg J.L., Wolbink G.J., Mansour K., Vissink A., Kallenberg C.G., Bootsma H. Rituximab treatment in patients with primary Sjogren’s syndrome: an open36. 37.
(check this in PDF content)
54
Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2005. – Vol. 52, N 1. – P. 262-268.
(check this in PDF content)
55
Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study // Arthritis Rheum. – 2005. – Vol. 52, N 2. – P. 601-607.
(check this in PDF content)
56
Schmidt E., Hunzelmann N., Zillikens D., Brocker E.B., Goebeler M. Rituximab in refractory autoimmune bullous diseases // Clin. Exp. Dermatol. – 2006. – Vol. 31, N 4. – P. 503-508.
(check this in PDF content)
57
Hoffman P.C. Immune hemolytic anemia – selected topics // Hematology Am. Soc. Hematol. Educ. Program. – 2006. – P. 13-18.
(check this in PDF content)
58
Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., Fraser G.A., Lim W., Kelton J.G. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura // Ann. Intern. Med. –
(check this in PDF content)
59
Bay A., Oner A.F., Uner A., Dogan M. Use of rituximab in chronic childhood immune thrombocytopenic purpura // Pediatr. Int. – 2006. – Vol. 48, N 5. – P. 514-516.
(check this in PDF content)
60
Kavanaugh A.F. B cell targeted therapies: safety considerations // J. Rheumatol. Suppl. – 2006. – Vol. 77. – P. 18-23. De Vita S., Zaja F., Sacco S., De Candia A.,
(check this in PDF content)
61
Fanin R., Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells // Arthritis Rheum. – 2002. – Vol. 46, N 8. – P. 2029-2033.
(check this in PDF content)
62
Kneitz C., Wilhelm M., Tony H.P. Improvement of refractory rheumatoid arthritis after depletion of B cells // Scand. J. Rheumatol. – 2004. – Vol. 33, N 2. – P. 82-86.
(check this in PDF content)
63
Moore J., Ma D., Will R., Cannell P., Handel M., Milliken S. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation // Bone Marrow Transplant. – 2004. – Vol. 34, N 3. –
(check this in PDF content)
64
Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis // Arthritis Rheum. – 2006. – Vol. 54, N 8. – P. 2377-2386.
(check this in PDF content)
65
Petschner F., Walker U.A., Schmitt-Graff A., Uhl M., Peter H.H. «Catastrophic systemic lupus erythematosus» with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/ rutuximab // Dtsch. Med. Wochenschr. – 2001. – Vol.
(check this in PDF content)
66
Perrotta S., Locatelli F., La Manna A.,
(check this in PDF content)
67
Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus // Br. J. Haematol. – 2002. – Vol. 116, N 2. – P. 465-467.
(check this in PDF content)
68
Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., Looney R.J. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus // Arthritis Rheum. –
(check this in PDF content)
69
Weide R., Heymanns J., Pandorf A., Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy // Lupus. – 2003. – Vol. 12, N 10. – P. 779-782.
(check this in PDF content)
70
Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., Tanaka Y. Downregulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab //
(check this in PDF content)
71
Edelbauer M., Jungraithmayr T., Zimmerhackl L.B. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report // Pediatr. Nephrol. – 2005. – Vol. 20, N 6. – P. 811-813.
(check this in PDF content)
72
Henriksson E., Sundelin B., Osterborg A., Jacobson S.H., Klareskog L. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (antiCD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond
(check this in PDF content)
73
Lambotte O., Durbach A., Kotb R., Ferlicot S., Delfraissy J.F., Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis // Clin Nephrol. – 2005. – Vol. 64, N 1. – P. 73-77.
(check this in PDF content)
74
Sabugo F., Llanos C., Soto L., Gutierrez J., Cuchacovich M. Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case // Rev. Med. Chil. – 2005. – Vol. 133, N 6. – P. 681-684.
(check this in PDF content)
75
Matthys E.G., Schurgers M., Vandecasteele S., De Vriese A. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature // Acta Clin. Belg. – 2005. – Vol. 60, N 2. – P. 102-105.
(check this in PDF content)
76
Marks S.D., Patey S., Brogan P.A., Hasson N., Pilkington C., Woo P., Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus // Arthritis Rheum. – 2005. – Vol. 52, N 10. – P. 3168-3174.
(check this in PDF content)
77
Armstrong D., Wright S., McVeigh C., Finch M. Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis? // Clin.
(check this in PDF content)
78
Lehembre S., Macario-Barrel A., Musette P., Carvalho P., Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus // Ann. Dermatol. Venereol. – 2006. – Vol. 133, N 1. – P. 53-55.
(check this in PDF content)
79
Lim S.W., Gillis D., Smith W., Hissaria P., Greville H., Peh C.A. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports // Intern. Med. J. – 2006. – Vol. 36, N 4. – P. 260-262.
(check this in PDF content)
80
Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Seve P. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases // Lupus. – 2006. –
(check this in PDF content)
81
Willems M., Haddad E., Niaudet P., Kone-
(check this in PDF content)
82
Paut I., Bensman A., Cochat P., Deschenes G., Fakhouri F., Leblanc T., Llanas B., Loirat C., Pillet P., Ranchin B., Salomon R., Ulinski T., Bader-Meunier B. Rituximab therapy for childhood-onset systemic lupus erythematosus // J. Pediatr. – 2006. – Vol. 148,
(check this in PDF content)
83
Jansson A.F., U. Wintergerst, E.D. Renner, B.H. Belohradsky. Rituximab-induced long-term remission in two children with SLE // Eur. J. Pediatr. – 2007. – Vol. 166, N 2. – P. 177-181.
(check this in PDF content)
84
Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and retreatment // Arthritis Rheum. – 2006. – Vol. 54, N 9. – P. 2970-
(check this in PDF content)
85
Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., Tsujimura S., Nawata M., Iwata S., Azuma T., Mimori T., Tanaka Y. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous
(check this in PDF content)
86
Kotani T., Takeuchi T., Kawasaki Y., Hirano S., Tabushi Y., Kagitani M., Makino S., Hanafusa T. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus // Lupus. – 2006. –
(check this in PDF content)
87
Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy // Arthritis Rheum. – 2001. – Vol. 44, N 12. – P. 2836-2840.
(check this in PDF content)
88
Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab // J. Intern. Med. – 2005. – Vol. 257, N 6. – P. 540-548.
(check this in PDF content)
89
Omdal R., Wildhagen K., Hansen T., Gunnarsson R., Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response // Scand. J. Rheumatol. – 2005. – Vol. 34, N 3. – P. 229-232.
(check this in PDF content)
90
Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial // Am. J. Respir. Crit. Care Med. – 2006. – Vol. 173, N 2. – P. 180-187.
(check this in PDF content)
91
Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., Lamprecht P., Gross W.L. Lack of efficacy of rituximab in Wegener’s granulo- matosis with refractory granulomatous manifesta- tions // Ann. Rheum. Dis. – 2006. – Vol. 65, N 7. –
(check this in PDF content)
92
Clatworthy M.R., Jayne D.R. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab // Am. J. Kidney Dis. – 2006. – Vol. 47, N 4. – P. 680-682.
(check this in PDF content)
93
Stasi R., Stipa E., Del Poeta G., Amadori S.,
(check this in PDF content)
94
Newland A.C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibodyassociated vasculitis treated with rituximab // Rheumatology (Oxford). – 2006. – Vol. 45, N 11. – P. 1432-1436.
(check this in PDF content)
95
Tektonidou M.G., Skopouli F.N. Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener’s granulomatosis // Clin. Exp. Rheumatol. – 2006. – Vol. 24, N 2, Suppl. 41. – P. S103.
(check this in PDF content)
96
Koukoulaki M., Smith K.G., Jayne D.R. Rituximab in Churg-Strauss syndrome // Ann. Rheum. Dis. – 2006. – Vol. 65, N 4. – P. 557-559.
(check this in PDF content)
97
Somer B.G., Tsai D.E., Downs L., Weinstein B., Schuster S.J. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma // Arthritis Rheum. – 2003. – Vol. 49, N 3. – P. 394-398.
(check this in PDF content)
98
Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., Candon S., Leguern V., Aouba A., Jean S., Gottenberg J.E., Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of
(check this in PDF content)
99
Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis // J. Clin. Rheumatol. – 2005. – Vol. 11, N 5. – P. 264-266.
(check this in PDF content)
100
Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis // J. Rheumatol. – 2006. – Vol. 33, N 5. – P. 1021-1026. 77.
(check this in PDF content)
101
Zaja F., Russo D., Fuga G., Patriarca F., Ermacora A., Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia // Haematologica. – 1999. – Vol. 84, N 12. – P. 1157-1158.
(check this in PDF content)
102
Arzoo K., Sadeghi S., Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) // Ann. Rheum. Dis. – 2002. – Vol. 61, N 10. – P. 922-924.
(check this in PDF content)
103
Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 // Blood. – 2003. – Vol. 101, N 10. – P. 3818-3826.
(check this in PDF content)
104
Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., Peters S.O., Gutzeit O., Arlt A.C., Solbach W., Gross W.L. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis // Ann.
(check this in PDF content)
105
Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., Cavallo R., Alpa M., Costanzo P., Giachino O., Mazzucco G., Sena L.M. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic
(check this in PDF content)
106
Catuogno M., Rezai S., Priori R., Magrini L., Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia // Rheumatology (Oxford). – 2005. – Vol. 44, N 3. – P. 406.
(check this in PDF content)
107
Kay J., McCluskey R.T. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency // N. Engl. J. Med. – 2005. – Vol. 353, N 15. – P. 1605-1613.
(check this in PDF content)
108
Cai F.Z., Ahern M., Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab // J. Rheumatol. – 2006. – Vol. 33, N 6. – P. 1197-1198.
(check this in PDF content)
109
Pekow J., Chung R.T. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab // J. Clin. Gastroenterol. – 2006. – Vol. 40, N 5. – P. 450.
(check this in PDF content)
110
Basse G., Ribes D., Kamar N., Mehrenberger M., Sallusto F., Esposito L., Guitard J., Lavayssiere L., Oksman F., Durand D., Rostaing L. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients // Transplant. Proc. – 2006. –
(check this in PDF content)
111
Cohen H., Green S., Jones S., Amos N., William B.D. Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia // Rheumatology (Oxford), 2006. 89.
(check this in PDF content)
112
Rubenstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome // J. Rheumatol. – 2006. – Vol. 33, N 2. – P. 355-357.
(check this in PDF content)
113
Anandacoomarasamy A., Gibson J., McGill N. «Cure» of life-threatening antiphospholipid syndrome with rituximab // Intern. Med. J. – 2006. – Vol. 36, N 7. – P. 474-475.
(check this in PDF content)
114
Ames P.R., Tommasino C., Fossati G., Scenna G., Brancaccio V., Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome // Ann. Hematol.,
(check this in PDF content)
115
Ahn E.R., Lander G., Bidot C.J., Jy W., Ahn Y.S. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy // Am. J. Hematol. – 2005. – Vol. 78, N 2. – P. 127-129.
(check this in PDF content)
116
Hongeng S., Tardtong P., Worapongpaiboon S., Ungkanont A., Jootar S. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab // Bone Marrow Transplant. –
(check this in PDF content)
117
Gupta N., Kavuru S., Patel D., Janson D., Driscoll N., Ahmed S., Rai K.R. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia // Leukemia. – 2002. – Vol. 16, N 10. – P. 2092-2095.
(check this in PDF content)
118
Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., Jankovic M., Pierani P., De
(check this in PDF content)
119
Stefano P., Bonora M.R., Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children // Blood. – 2003. – Vol. 101, N 10. – P. 3857-3861.
(check this in PDF content)
120
Motto D.G., Williams J.A., Boxer L.A. Rituximab for refractory childhood autoimmune hemolytic anemia // Isr. Med. Assoc. J. – 2002. – Vol. 4, N 11. – P. 1006-1008.
(check this in PDF content)
121
Gottardo N.G., Baker D.L., Willis F.R. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab // Pediatr. Hematol. Oncol. – 2003. – Vol. 20, N 7. – P. 557-561.
(check this in PDF content)
122
Endo T., Nakao S., Koizumi K., Nishio M., Fujimoto K., Sakai T., Kumano K., Obara M., Koike T. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal
(check this in PDF content)
123
Shanafelt T.D., Madueme H.L., Wolf R.C., Tefferi A. Rituximab for immune cytopenia in adults: 100. 101. 102.
(check this in PDF content)
124
Raj A., Bertolone S., Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease // J. Pediatr. Hematol. Oncol. – 2004. – Vol. 26, N 5. –
(check this in PDF content)
125
Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome // Haematologica. – 2004. – Vol. 89, N 9. – P. ECR34.
(check this in PDF content)
126
Narat S., Gandla J., Hoffbrand A.V., Hughes R.G., Mehta A.B. Rituximab in the treatment of refractory autoimmune cytopenias in adults // Haematologica. – 2005. – Vol. 90, N 9. – P. 1273-1274. van Daalen S.T., van Dijken P.J., Tamminga R.Y.,
(check this in PDF content)
127
Brons P.P. Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia // Ned. Tijdschr. Geneeskd. – 2005. – Vol. 149, N 42. – P. 2350-2354.
(check this in PDF content)
128
Nishida H., Murase T., Ueno H., Park J.W., Yano T., Ikeda Y. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia // Leuk. Res. – 2006. – Vol. 30, N 12. – P. 1589-1590.
(check this in PDF content)
129
Pamuk G.E., Turgut B., Demir M., Tezcan F., Vural O. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia // Am. J. Hematol. – 2006. – Vol. 81, N 8. – P. 631-
(check this in PDF content)
130
Saleh M.N., Gutheil J., Moore M., Bunch P.W., Butler J., Kunkel L., Grillo-Lopez A.J., LoBuglio A.F. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia // Semin. Oncol. – 2000. – Vol. 27,
(check this in PDF content)
131
Shvidel L., Klepfish A., Berrebi A. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with lowgrade non-Hodgkin’s lymphoma // Am. J. Hematol. – 2001. – Vol. 67, N 3. – P. 213-214.
(check this in PDF content)
132
Faurschou M., Hasselbalch H.C., Nielsen O.J. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia // Eur. J. Haematol. – 2001. – Vol. 66,
(check this in PDF content)
133
Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura // Blood. – 2001. – Vol. 98, N 4. – P. 952-957.
(check this in PDF content)
134
Abdel-Raheem M.M., Potti A., Kobrinsky N. Severe Evans’s syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal antiCD20 antibody // Ann. Hematol. – 2001. – Vol. 80, N 9. – P. 543-545.
(check this in PDF content)
135
Zaja F., Iacona I., Masolini P., Russo D., Sperotto A., Prosdocimo S., Patriarca F., de Vita S.,
(check this in PDF content)
136
Regazzi M., Baccarani M., Fanin R. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia // Haematologica. – 2002. – Vol. 87, N 2. – P. 189-195.
(check this in PDF content)
137
Delgado J., Bustos J.G., Jimenez-Yuste V., Hernandez-Navarro F. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura // Haematologica. – 2002. – Vol. 87, N 2. – P. 215-216.
(check this in PDF content)
138
Cohen Y., Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab // Hematol. J. – 2002. – Vol. 3, N 1. – P. 61-62.
(check this in PDF content)
139
Meo P., Stipa E., La Presa M., Bianchi M., Di Giulio C., Stasi R., Amadori S. Rituximab treatment of chronic idiopathic thrombocytopenic purpura.
(check this in PDF content)
140
Results of a phase II study // Recenti Prog. Med. – 2002. – Vol. 93, N 7-8. – P. 421-427.
(check this in PDF content)
141
Giagounidis A.A., Anhuf J., Schneider P., Germing U., Sohngen D., Quabeck K., Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study // Eur. J. Haematol. – 2002. –
(check this in PDF content)
142
Iodice G., Tartarone A., Matera R., Di Renzo N. Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab // Leuk. Lymphoma. – 2003. – Vol. 44, N 3. – P. 561-562.
(check this in PDF content)
143
Riksen N.P., Keuning J.J., Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura // Neth. J. Med. – 2003. – Vol. 61, N 7. – P. 262-265.
(check this in PDF content)
144
Bengtson K.L., Skinner M.A., Ware R.E. Successful use of anti-CD20 (rituximab) in severe, lifethreatening childhood immune thrombocytopenic purpura // J. Pediatr. – 2003. – Vol. 143, N 5. – P. 670-673.
(check this in PDF content)
145
Thude H., Gruhn B., Werner U., Schorner U., Hafer R., Zintl F., Barz D. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis // Acta Haematol. – 2004. – Vol. 111, N 4. – P. 221-224.
(check this in PDF content)
146
Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., Bussel J.B. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with 121.
(check this in PDF content)
147
Pusiol A., Cesaro S., Nocerino A., Picco G., Zanesco L., Bisogno G. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia // Eur. J. Pediatr. – 2004. – Vol. 163, N 6. – P. 305-307.
(check this in PDF content)
148
Koulova L., Alexandrescu D., Dutcher J.P., O’Boyle K.P., Eapen S., Wiernik P.H. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases //
(check this in PDF content)
149
Tanai C., Iki S., Nakahara F., Iijima K., Usuki K., Kuwana M., Urabe A. Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura // Rinsho Ketsueki. – 2004. – Vol. 45, N 11. – P. 1181-1186.
(check this in PDF content)
150
Lalayanni C., Stavroyianni N., Saloum R., Tsompanakou A., Anagnostopoulos A. Rituximab is effective for selected patients with chronic steroidrefractory immune thrombocytopenic purpura // Hematology. – 2004. – Vol. 9, N 4. – P. 287-289.
(check this in PDF content)
151
Taube T., Schmid H., Reinhard H., von Stackelberg A., Overberg U.S. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood // Haematologica. – 2005. – Vol. 90, N 2. – P. 281-283.
(check this in PDF content)
152
Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., Andersen I., Schmidt K., Andersen T.M., Peterslund N.A., Birgens H.S., Plesner T., Pedersen B.B., Hasselbalch H.C. Rituximab chimeric anti-CD20 monoclonal
(check this in PDF content)
153
Moschovi M., Trimis G., Pergantou H., Platokouki H., Vrachnou E., Tzortzatou-Stathopoulou F. Clinical remission following monoclonal antiCD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura //
(check this in PDF content)
154
Carbone J., Escudero A., Mayayo M., Ballesteros M., Perez-Corral A., Sanchez-Ramon S., Sarmiento E., Micheloud D., Fernandez-Cruz E. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic
(check this in PDF content)
155
Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., Sawaf H., Moore T.B., Loh M.L., Glader B.E., McCarthy M.C., Mueller B.U., Olson T.A., Lorenzana A.N., Mentzer W.C., Buchanan G.R., Feldman H.A., Neufeld
(check this in PDF content)
156
Ojeda-Uribe M., Brunot A., Issler M. Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case // Rev. Med. Chil. – 2005. – Vol. 133, N 11. –
(check this in PDF content)
157
Penalver F.J., Jimenez-Yuste V., Almagro M., Alvarez-Larran A., Rodriguez L., Casado M., Gallur L., Giraldo P., Hernandez R., Menor D., Rodriguez M.J., Caballero D., Gonzalez R., Mayans J., Millan I., Cabrera J.R. Rituximab in the management of
(check this in PDF content)
158
Taylor R.M., Bockenstedt P., Su G.L., Marrero J.A., Pellitier S.M., Fontana R.J. Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature // Liver Transpl. – 2006. – Vol. 12, N 5. – P. 781-791.
(check this in PDF content)
159
Parodi E., Nobili B., Perrotta S., Rosaria
(check this in PDF content)
160
Matarese S.M., Russo G., Licciardello M., Zecca M., Locatelli F., Cesaro S., Bisogno G., Giordano P., De Mattia D., Ramenghia U. Rituximab (anti- CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombo-
(check this in PDF content)
161
Latifzadeh S.Z., Entezari V. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and antiCD20 monoclonal antibody: a case report // Clin. Appl. Thromb. Hemost. – 2006. – Vol. 12, N 4. – P. 489-492.
(check this in PDF content)
162
Wiestner, A., Cho H.J., Asch A.S., Michelis M.A., Zeller J.A., Peerschke E.I., Weksler B.B., Schechter G.P. Rituximab in the treatment of acquired factor VIII inhibitors // Blood. – 2002. – Vol. 100, N 9. – P. 3426-3428.
(check this in PDF content)
163
Kain S., Copeland T.S., LeahyM.F. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab) // Br. J. Haematol. – 2002. – Vol. 119, N 2. – P. 578.
(check this in PDF content)
164
Marietta M., Pozzi S., Luppi M., Bertesi M., Cappi C., Morselli M., Torelli G. Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman’s disease: a case report // Eur. J. Haematol. – 2003. – Vol. 70, N 3. – P. 181-182.
(check this in PDF content)
165
Stasi R., Brunetti M., Stipa E., Amadori S. Selective B-cell depl etion with rituximab for the treatment of patients with acquired hemophilia // Blood. – 2004. – Vol. 103, N 12. – P. 4424-4428. 141.
(check this in PDF content)
166
Huang Y.W., Saidi P., Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases // Haemophilia. – 2004. – Vol. 10, N 6. – P. 713-721.
(check this in PDF content)
167
Holme P.A., Brosstad F., Tjonnfjord G.E. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies // Haemophilia. – 2005. – Vol. 11, N 5. – P. 510-515.
(check this in PDF content)
168
Abdallah A., Coghlan D.W., Duncan E.M., Chunilal S.D., Lloyd J.V. Rituximab-induced longterm remission in patients with refractory acquired hemophilia // J. Thromb. Haemost. – 2005. – Vol. 3, N 11. – P. 2589-2590.
(check this in PDF content)
169
Berezne A., Stieltjes N., Le-Guern V., Teixeira L., Billy C., Roussel-Robert V., Flaujac C., Horellou M.H., Guillevin L., Mouthon L. Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases //
(check this in PDF content)
170
Rojas-Garcia R., Gallardo E., de Andres I., de Luna N., Juarez C., Sanchez P., Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab // Neurology. – 2003. – Vol. 61, N 12. – P. 1814-1816.
(check this in PDF content)
171
Ruegg S.J., Fuhr P., Steck A.J. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg // Neurology. – 2004. – Vol. 63, N 11. – P. 2178-2179.
(check this in PDF content)
172
Goldfarb A.R., Weimer L.H., Brannagan, 3rd T.H. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy // Muscle Nerve. – 2005. – Vol. 31, N 4. – P. 510-515.
(check this in PDF content)
173
Broglio L., Lauria G. Worsening after rituximab treatment in anti-mag neuropathy // Muscle Nerve. – 2005. – Vol. 32, N 3. – P. 378-379.
(check this in PDF content)
174
Kilidireas C., Anagnostopoulos A., Karandreas N., Mouselimi L., Dimopoulos M.A. Rituximab therapy in monoclonal IgM-related neuropathies // Leuk. Lymphoma. – 2006. – Vol. 47, N 5. – P. 859-864.
(check this in PDF content)
175
Kelly J.J. Chronic peripheral neuropathy responsive to rituximab // Rev. Neurol. Dis. – 2006. – Vol. 3, N 2. – P. 78-81.
(check this in PDF content)
176
Gorson K.C., Natarajan N., Ropper A.H., Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial // Muscle Nerve. – 2007. – Vol. 35, N 1. – P. 66-69.
(check this in PDF content)
177
Zaja F., Russo D., Fuga G., Perella G., Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant // Neurology. – 2000. – Vol. 55, N 7. – P. 1062-1063.
(check this in PDF content)
178
Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report // J. Pediatr. – 2003. – Vol. 143, N 5. – P. 674-677.
(check this in PDF content)
179
Gajra A., Vajpayee N., Grethlein S.J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma // Am. J. Hematol. – 2004. – Vol. 77, N 2. – P. 196-197.
(check this in PDF content)
180
Takagi K., Yoshida A., Iwasaki H., Inoue H., Ueda T. Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma // Ann. Hematol. – 2005. – Vol. 84, N 8. – P. 548-550.
(check this in PDF content)
181
Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab // Muscle Nerve. – 2006. – Vol. 33, N 4. – P. 575-580.
(check this in PDF content)
182
Borradori L., Lombardi T., Samson J., Girardet C., Saurat J.H., Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus //
(check this in PDF content)
183
Salopek T.G., Logsetty S., Tredget E.E. Anti- CD20 chimeric monoclonal anti-body (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder // J. Am. Acad. Dermatol. –
(check this in PDF content)
184
Herrmann G., Hunzelmann N., Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab) // Br. J. Dermatol. – 2003. – Vol. 148, N 3. – P. 602-603.
(check this in PDF content)
185
Cooper H.L., Healy E., Theaker J.M., Friedmann P.S. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) // Clin. Exp. Dermatol. – 2003. – Vol. 28, N 4. – P. 366-368.
(check this in PDF content)
186
Goebeler M., Herzog S., Brocker E.B., Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab // Br. J. Dermatol. – 2003. – Vol. 149, N 4. – P. 899-901.
(check this in PDF content)
187
Dupuy A., Viguier M., Bedane C., Cordoliani F., Blaise S., Aucouturier F., Bonnetblanc J.M., Morel P., Dubertret L., Bachelez H. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) // Arch. Dermatol. – 2004. –
(check this in PDF content)
188
Espana A., Fernandez-Galar M., Lloret P., Sanchez-Ibarrola A., Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations // J. Am. Acad.
(check this in PDF content)
189
Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab) // J. Am. Acad. Dermatol. – 2004. – Vol. 51, N 5. – P. 817-819. 163.
(check this in PDF content)
190
Wenzel J., Bauer R., Bieber T., Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants // Acta Derm. Venereol. – 2005. – Vol. 85, N 2. – P. 185-186.
(check this in PDF content)
191
Arin M.J., Engert A., Krieg T., Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus // Br. J. Dermatol. – 2005. – Vol. 153, N 3. – P. 620-625.
(check this in PDF content)
192
Kong H.H., Prose N.S., Ware R.E., Hall, 3rd, R.P. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab) // Pediatr. Dermatol. – 2005. – Vol. 22, N 5. – P. 461-464.
(check this in PDF content)
193
Cecchi R., Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J. Dermatol. – 2005. – Vol. 32, N 10. – P. 862-864.
(check this in PDF content)
194
Esposito M., Capriotti E., Giunta A., Bianchi L., Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab // Acta Derm. Venereol. – 2006. – Vol. 86, N 1. – P. 87-89.
(check this in PDF content)
195
Niedermeier A., Worl P., Barth S., Schuler G., Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment // Eur. J. Dermatol. – 2006. – Vol. 16, N 3. – P. 266-270.
(check this in PDF content)
196
Borel C., Launay F., Garrouste C., Astudillo L., Bazex J., Arlet P., Paul C., Viraben R., Sailler L. Rituximab induced remission of pemphigus vulgaris: 2 cases // Rev. Med. Interne, 2006.
(check this in PDF content)
197
Ahmed A.R., Spigelman Z., Cavacini L.A., Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin // N. Engl. J. Med. – 2006. – Vol. 355, N 17. – P. 1772-1779.
(check this in PDF content)
198
Salvi M., Vannucchi G., Campi I., Rossi S., Bonara P., Sbrozzi F., Guastella C., Avignone S., Pirola G., Ratiglia R., Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell
(check this in PDF content)
199
Saigal K., Valencia I.C., Cohen J., Kerdel F.A. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab // J. Am. Acad. Dermatol. – 2003. – Vol. 49, N 5, Suppl. –
(check this in PDF content)
200
Levi M., Hack C.E., van Oers M.H. Rituximabinduced elimination of acquired angioedema due to C1-inhibitor deficiency // Am. J. Med. – 2006. – Vol. 119, N 8. – P. e3-e5.
(check this in PDF content)
201
Ratanatharathorn V., Ayash L., Reynolds C., Silver S., Reddy P., Becker M., Ferrara J.L., Uberti J.P. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody // Biol. Blood Marrow Transplant. – 2003. – Vol. 9, N 8. –
(check this in PDF content)
202
Okamoto M., Okano A., Akamatsu S., Ashihara E., Inaba T., Takenaka H., Katoh N., Kishimoto S., Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graftversus-host disease // Leukemia. – 2006. 20, N 1. –
(check this in PDF content)
203
Cutler C., Miklos D., Kim H.T., Treister N., Woo S.B., Bienfang D., Klickstein L.B., Levin J., 186. 187.
(check this in PDF content)
204
Miller K., Reynolds C., Macdonell R., Pasek M., Lee S.J., Ho V., Soiffer R., Antin J.H., Ritz J., Alyea E. Rituximab for steroid-refractory chronic graftversus-host disease // Blood. – 2006. 108, N 2. – P. 756-762.
(check this in PDF content)